Total EVs and L1CAM-enriched EVs (L1CAM+ EVs) were analyzed in serum samples from 25 newly diagnosed, treatment-naïve RRMS patients at baseline (month 0) and after six months (month 6) of rituximab therapy, who all showed no signs of new disease activity. This evidence concerns the gene L1CAM and relapsing-remitting multiple sclerosis.